1. Targets and treatments in primary CNS lymphoma.
- Author
-
von Roemeling C, Ferreri AJM, Soussain C, Tun HW, and Grommes C
- Subjects
- Humans, Signal Transduction drug effects, Lymphoma therapy, Lymphoma drug therapy, Lymphoma diagnosis, Lymphoma pathology, Lymphoma genetics, Lymphoma etiology, Disease Management, Central Nervous System Neoplasms therapy, Central Nervous System Neoplasms drug therapy, Central Nervous System Neoplasms pathology, Central Nervous System Neoplasms diagnosis, Molecular Targeted Therapy methods
- Abstract
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma entirely localized in the central nervous system or vitreoretinal space. PCNSL generally initially responds to methotrexate-containing chemotherapy regimens, but progressive or relapsing disease is common, and the prognosis is poor for relapsed or refractory (R/R) patients. PCNSL is often characterized by activation of nuclear factor kappa B (NF-κB) due to mutations in the B-cell receptor (BCR) or toll-like receptor (TLR) pathways, as well as immune evasion. Targeted treatments that inhibit key PCNSL mechanisms and pathways are being evaluated; inhibition of Bruton's tyrosine kinase (BTK) downstream of BCR activation has demonstrated promising results in treating R/R disease. This review will summarize the evidence and potential for targeted therapeutic agents to improve treatment outcomes in PCNSL. This includes immunotherapeutic and immunomodulatory approaches and inhibitors of the key pathways driving PCNSL, such as aberrant BCR and TLR signaling.
- Published
- 2024
- Full Text
- View/download PDF